Latest thrombocytopenic purpura Stories
Market Size - $381.99 million in 2013, Market Growth - CAGR of 5.9%, Market Trends - Growing usage rates of combination therapy - New report published by Grand View Research.
Thrombotic thrombocytopenic purpura (TTP) is a potentially-fatal blood disorder that causes blood clots to form in small blood vessels that affect many organs including the liver, kidneys, heart, pancreas, and brain.
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease of the blood system.
Protalex, Inc. (OTCBB:PRTX) today announced that Steven H. Kane, President and Chief Executive Officer, will present at the upcoming Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008 at 3:40 p.m. Eastern Time.
Amgen has announced that the FDA has approved Nplate, the first and only platelet producer for the treatment of thrombocytopenia in splenectomized and non-splenectomized adults with chronic immune thrombocytopenic purpura.
Symphogen and Biovitrum have announced the recruitment of the first patient into a Phase II clinical trial, initiated in June 2008 to evaluate the safety and efficacy, and explore the dose range of Sym001 in idiopathic thrombocytopenic purpura patients.
Amgen has announced new positive data from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura, a chronic and serious autoimmune disorder characterized by low platelet counts in the blood.